Skip to main content
. 2021 Aug 10;71(3):719–726. doi: 10.1007/s00262-021-03031-1

Fig. 5.

Fig. 5

Meta-analysis of overall survival of patients with advanced NSCLCs treated with second-line anti-PD-(L)1 with chemotherapy or without vs. chemotherapy alone (control). ABCP atezolizumab, bevacizumab, carboplatin, paclitaxel), ACP: atezolizumab, bevacizumab, carboplatin, paclitaxel